JP2018514187A - 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法 - Google Patents

発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法 Download PDF

Info

Publication number
JP2018514187A
JP2018514187A JP2017546066A JP2017546066A JP2018514187A JP 2018514187 A JP2018514187 A JP 2018514187A JP 2017546066 A JP2017546066 A JP 2017546066A JP 2017546066 A JP2017546066 A JP 2017546066A JP 2018514187 A JP2018514187 A JP 2018514187A
Authority
JP
Japan
Prior art keywords
risk
genes
disease
sample
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017546066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514187A5 (enExample
Inventor
ジュリア シー． ケネディー
ジュリア シー． ケネディー
モライマ パガン
モライマ パガン
チュー−ファン リン
チュー−ファン リン
チン ファン
チン ファン
ピー． ショーン ウォルシュ
ピー． ショーン ウォルシュ
新 松崎
新 松崎
ケビン トラバース
ケビン トラバース
ス ヨン キム
ス ヨン キム
Original Assignee
ベラサイト インコーポレイテッド
ベラサイト インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベラサイト インコーポレイテッド, ベラサイト インコーポレイテッド filed Critical ベラサイト インコーポレイテッド
Publication of JP2018514187A publication Critical patent/JP2018514187A/ja
Publication of JP2018514187A5 publication Critical patent/JP2018514187A5/ja
Priority to JP2022002016A priority Critical patent/JP2022050571A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2017546066A 2015-03-04 2016-03-03 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法 Withdrawn JP2018514187A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022002016A JP2022050571A (ja) 2015-03-04 2022-01-11 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562128469P 2015-03-04 2015-03-04
US201562128463P 2015-03-04 2015-03-04
US62/128,463 2015-03-04
US62/128,469 2015-03-04
US201562238893P 2015-10-08 2015-10-08
US62/238,893 2015-10-08
PCT/US2016/020583 WO2016141127A1 (en) 2015-03-04 2016-03-03 Methods for assessing the risk of disease occurrence or recurrence using expression level and sequence variant information

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022002016A Division JP2022050571A (ja) 2015-03-04 2022-01-11 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法

Publications (2)

Publication Number Publication Date
JP2018514187A true JP2018514187A (ja) 2018-06-07
JP2018514187A5 JP2018514187A5 (enExample) 2019-04-11

Family

ID=56849098

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017546066A Withdrawn JP2018514187A (ja) 2015-03-04 2016-03-03 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法
JP2022002016A Pending JP2022050571A (ja) 2015-03-04 2022-01-11 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022002016A Pending JP2022050571A (ja) 2015-03-04 2022-01-11 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法

Country Status (7)

Country Link
US (1) US20180016642A1 (enExample)
EP (1) EP3265588A4 (enExample)
JP (2) JP2018514187A (enExample)
CN (2) CN114634985A (enExample)
AU (1) AU2016226253A1 (enExample)
CA (1) CA2978442A1 (enExample)
WO (1) WO2016141127A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021256525A1 (ja) * 2020-06-18 2021-12-23 国立研究開発法人産業技術総合研究所 情報処理システム、情報処理方法、同定方法及びプログラム
JP2022547735A (ja) * 2019-09-16 2022-11-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 乳房がんの分子特徴付けに基づく処置の方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP2430574A1 (en) 2009-04-30 2012-03-21 Patientslikeme, Inc. Systems and methods for encouragement of data submission in online communities
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US20250263795A1 (en) * 2009-05-07 2025-08-21 Veracyte, Inc. Methods for classification of tissue samples as positive or negative for cancer
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CN109074426B (zh) 2016-02-12 2022-07-26 瑞泽恩制药公司 用于检测异常核型的方法和系统
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US20190264264A1 (en) * 2016-10-26 2019-08-29 Integrated Nano-Technologies, Inc. Systems and methods for analyzing rna transcripts
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018152093A1 (en) * 2017-02-15 2018-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of diagnosing cancer using mitochondrial dna heterogeneity
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019023517A2 (en) * 2017-07-27 2019-01-31 Veracyte, Inc. GENOMIC SEQUENCING CLASSIFIER
US12417825B2 (en) 2017-09-15 2025-09-16 Alden Scientific, Inc. Systems and methods for collecting and analyzing comprehensive medical information
CN108416190A (zh) * 2018-02-11 2018-08-17 广州市碳码科技有限责任公司 基于深度学习的肿瘤早期筛查方法、装置、设备及介质
CN112585270B (zh) * 2018-08-15 2023-12-05 中国科学院遗传与发育生物学研究所 评估或改善脑功能、学习能力或记忆力的组合物和方法
AU2019356497B2 (en) * 2018-10-08 2025-06-26 Freenome Holdings, Inc. Transcription factor profiling
US11894139B1 (en) * 2018-12-03 2024-02-06 Patientslikeme Llc Disease spectrum classification
GB201914193D0 (en) * 2019-10-02 2019-11-13 Aldo Faisal Digital biomarkers of movement for diagnosis
JP7721538B2 (ja) 2020-01-09 2025-08-12 ホワイトラビット・エーアイ・インコーポレイテッド リアルタイム放射線医学を行うための方法およびシステム
CN112326965B (zh) * 2020-10-22 2022-03-04 南京医科大学 Daam1蛋白在制备肾透明细胞癌诊断及预后评估试剂盒中的应用
CN114622007A (zh) * 2020-12-10 2022-06-14 深圳先进技术研究院 一种Cox6c检测引物及其应用
US11367521B1 (en) 2020-12-29 2022-06-21 Kpn Innovations, Llc. System and method for generating a mesodermal outline nourishment program
CN112715484B (zh) * 2020-12-29 2022-04-22 四川省人民医院 构建视网膜色素变性疾病模型的方法、应用以及繁育方法
CN113504370B (zh) * 2021-06-29 2024-02-09 广州金研生物医药研究院有限公司 Mapk15蛋白在前列腺癌的恶性程度或预后程度预测中的应用
US20250259750A1 (en) * 2022-04-15 2025-08-14 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification
WO2024186815A1 (en) * 2023-03-06 2024-09-12 Exactech, Inc. Improved computer-based joint arthroplasty system and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510975A (ja) * 1997-07-01 2002-04-09 アンスティテュ パストゥール ドゥ リール アルツハイマー病の診断方法
US20110312520A1 (en) * 2010-05-11 2011-12-22 Veracyte, Inc. Methods and compositions for diagnosing conditions
JP2013212052A (ja) * 2012-03-30 2013-10-17 Yale Univ Ｋｒａｓバリアントおよび腫瘍生物学

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
US20130303826A1 (en) * 2011-01-11 2013-11-14 University Health Network Prognostic signature for oral squamous cell carcinoma
EP2771487A1 (en) * 2011-10-27 2014-09-03 Asuragen, INC. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510975A (ja) * 1997-07-01 2002-04-09 アンスティテュ パストゥール ドゥ リール アルツハイマー病の診断方法
US20110312520A1 (en) * 2010-05-11 2011-12-22 Veracyte, Inc. Methods and compositions for diagnosing conditions
JP2013212052A (ja) * 2012-03-30 2013-10-17 Yale Univ Ｋｒａｓバリアントおよび腫瘍生物学

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALI SZ., ET AL., "USE OF THE AFIRMA GENE EXPRESSION CLASSIFIER FOR PREOPERATIVE IDENTIFICATION OF BE, JPN6020014081, 11 February 2013 (2013-02-11), ISSN: 0004590159 *
NAT COMMUN., 2015 JAN 9, VOL. 6, ARTICLE NO. 5901 (PP. 1-11), JPN6020014086, ISSN: 0004590160 *
ONCOTARGET, 2015 OCT 9, VOL. 6, NO. 42, PP. 44971-44984, JPN6020014089, ISSN: 0004422022 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547735A (ja) * 2019-09-16 2022-11-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 乳房がんの分子特徴付けに基づく処置の方法
WO2021256525A1 (ja) * 2020-06-18 2021-12-23 国立研究開発法人産業技術総合研究所 情報処理システム、情報処理方法、同定方法及びプログラム
JP2021197100A (ja) * 2020-06-18 2021-12-27 国立研究開発法人産業技術総合研究所 情報処理システム、情報処理方法、同定方法及びプログラム
JP7570088B2 (ja) 2020-06-18 2024-10-21 国立研究開発法人産業技術総合研究所 情報処理システム、情報処理方法、同定方法及びプログラム

Also Published As

Publication number Publication date
WO2016141127A1 (en) 2016-09-09
EP3265588A1 (en) 2018-01-10
CN114634985A (zh) 2022-06-17
AU2016226253A1 (en) 2017-09-21
US20180016642A1 (en) 2018-01-18
EP3265588A4 (en) 2018-10-10
CA2978442A1 (en) 2016-09-09
CN107636171A (zh) 2018-01-26
JP2022050571A (ja) 2022-03-30

Similar Documents

Publication Publication Date Title
JP2022050571A (ja) 発現レベルおよび配列変種情報を用いて疾患の発症または再発のリスクを評価するための方法
JP7022188B2 (ja) 無細胞核酸の多重解像度分析のための方法
US20180349548A1 (en) Methods and compositions that utilize transcriptome sequencing data in machine learning-based classification
JP6684775B2 (ja) 甲状腺状態の診断のための方法および組成物
JP6227095B2 (ja) 遺伝的変異の非侵襲的評価のための方法およびプロセス
JP6680680B2 (ja) 染色体変化の非侵襲性評価のための方法およびプロセス
US20230175058A1 (en) Methods and systems for abnormality detection in the patterns of nucleic acids
ES2907069T3 (es) Resolución de fracciones genómicas usando recuentos de polimorfismos
US9495515B1 (en) Algorithms for disease diagnostics
CN112534506B (zh) 组织特异性的甲基化标志物
JP2018196389A (ja) 遺伝子の変動の非侵襲的評価のための方法および処理
JP2022527316A (ja) ウィルスに関連した癌のリスクの層別化
US20250263795A1 (en) Methods for classification of tissue samples as positive or negative for cancer
WO2024258639A1 (en) Methods and systems of classifying tumor tissue samples
HK40042779A (en) Tissue-specific methylation marker
HK1182452B (en) Methods and compositions for diagnosing conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210908

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220111

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220120

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230111

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230912

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20231214